# US 8,277,822 B2 · Botulinum toxin treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,822 B2
- Document ID: US8277822B2
- Status: Granted
- Kind: B2
- Application number: 12/155,104
- Filed: 2008-05-29
- Published: 2009-01-29
- Granted: 2012-10-02
- Earliest claimed: 2003-12-04
- Assignees: Ipsen Biopharm Ltd.
- Inventors: Chris Dott; John Batchelor; Pierre Bernard D'Arbigny; Roland Cherif-Cheikh
- Web page: https://patentgrep.com/patent/US8277822B2

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61P 13/06: Anti-spasmodics
- A61P 13/10: of the bladder
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A liquid or semi-solid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterized by bladder spasms (e.g. urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor sphincter, urinary retention secondary to spastic sphincter or hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis or characterized by a spasm reflex), wherein said medicament is for administration by infusion into the bladder or by other methods that do not involve injection into the bladder wall.

## Claims

### Claim 1

A method of treating a bladder spasm disorder in a patient comprising administering an effective amount of botulinum toxin to a patient in need thereof, the method comprising spreading a solid, semi-solid or liquid formulation of botulinum toxin onto an outer wall of a balloon; inserting the balloon into the bladder of the patient; and, contacting the wall of the bladder by inflating the balloon.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bladder spasm disorder is selected from the group consisting of urinary incontinence due to unstable bladder of unstable detrusor sphincter, voiding complications due to detrusor overactivity of unstable detrusor sphincter, urinary retention secondary to spastic sphincter of hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the liquid or semi-solid formulation of botulinum toxin has a volume of 20 to 80 ml.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the liquid or semi-solid formulation of botulinum toxin contains from 100 to 2500 units of botulinum toxin type A.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the liquid or semi-solid formulation contains from 4,000 to 50,000 units of botulinum toxin type B.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the semi-solid formulation is in the form of a gel formulation.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the formulation is in the form of a spray formulation.

### Claim 8 (depends on 1)

The method of treatment according to claim 1, wherein the disorder is urinary incontinence due to unstable bladder, the formulation is in the form of semi-solid formulation, and the botulinum toxin is botulinum toxin type A.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the bladder spasm disorder is voiding complications due to detrusor overactivity or unstable detrusor sphincter.
